Drug Profile
Folic acid intravenous - Endocyte
Alternative Names: IV folic acid - Endocyte; NeocepriLatest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Endocyte
- Class Antianaemics; Antidotes; Chemoprotectants; Chemosensitisers; Diagnostic agents; Pterins; Small molecules; Vitamins
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Ovarian cancer
Most Recent Events
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 16 May 2014 Regulatory submission withdrawn for Diagnostic imaging (patients with folate receptor-positive ovarian cancer) in European Union (IV) ,
- 16 May 2014 Regulatory submission withdrawn for Ovarian cancer (diagnosis of patients with folate receptor-positive ovarian cancer) in European Union (IV) ,